Attainment of Target Antibiotic Levels by Oral Treatment of Left-Sided Infective Endocarditis: A POET Substudy
Authors:
- 22 March 2023
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 77 (2) , 242-251
Abstract
Background: In the POET (Partial Oral Endocarditis Treatment) trial, oral step-down therapy was noninferior to full-length intravenous antibiotic administration. The aim of the present study was to perform pharmacokinetic/pharmacodynamic analyses for oral treatments of infective endocarditis to assess the probabilities of target attainment (PTAs). Methods: Plasma concentrations of oral antibiotics were measured at day 1 and 5. Minimal inhibitory concentrations (MICs) were determined for the bacteria causing infective endocarditis (streptococci, staphylococci, or enterococci). Pharmacokinetic/pharmacodynamic targets were predefined according to literature using time above MIC or the ratio of area under the curve to MIC. Population pharmacokinetic modeling and pharmacokinetic/pharmacodynamic analyses were done for amoxicillin, dicloxacillin, linezolid, moxifloxacin, and rifampicin, and PTAs were calculated. Results: A total of 236 patients participated in this POET substudy. For amoxicillin and linezolid, the PTAs were 88%–100%. For moxifloxacin and rifampicin, the PTAs were 71%–100%. Using a clinical breakpoint for staphylococci, the PTAs for dicloxacillin were 9%–17%. Seventy-four patients at day 1 and 65 patients at day 5 had available pharmacokinetic and MIC data for 2 oral antibiotics. Of those, 13 patients at day 1 and 14 patients at day 5 did only reach the target for 1 antibiotic. One patient did not reach target for any of the 2 antibiotics. Conclusions: For the individual orally administered antibiotic, the majority reached the target level. Patients with sub-target levels were compensated by the administration of 2 different antibiotics. The findings support the efficacy of oral step-down antibiotic treatment in patients with infective endocarditis.Keywords
Funding Information
- Danish Heart Foundation
- Capital Regions Research Council
- Hartmann’s Foundation
- Svend Andersens Foundation
- Novo Nordisk Foundation
- Borregaard Clinical Scientist Fellowship (NNF17OC0025074)
This publication has 35 references indexed in Scilit:
- Partial oral treatment of endocarditisAmerican Heart Journal, 2013
- Infective endocarditisNature Reviews Cardiology, 2011
- Clinical Implications of Pharmacokinetics and Pharmacodynamics of FluoroquinolonesClinical Infectious Diseases, 2005
- Excretion of β-Lactam Antibiotics in Sweat—a Neglected Mechanism for Development of Antibiotic Resistance?Antimicrobial Agents and Chemotherapy, 2000
- Moxifloxacin (Bay 12-8039): a new methoxy quinolone antibacterialExpert Opinion on Investigational Drugs, 1999
- Dicloxacillin and flucloxacillin: Pharmacokinetics, protein binding and serum bactericidal titers in healthy subjects after oral administrationInfection, 1995
- Evaluation of New Anti-Infective Drugs for the Treatment of Infective EndocarditisClinical Infectious Diseases, 1992
- Treatment of infective endocarditis—1973Progress in Cardiovascular Diseases, 1973
- The Lewis A. Conner Lecture of the American Heart AssociationCirculation, 1950
- THE TREATMENT OF SUBACUTE BACTERIAL ENDOCARDITIS WITH PENICILLIN 1Journal of Clinical Investigation, 1945